Literature DB >> 28880488

Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis.

Hidenori Toyoda1, Atsushi Hiraoka2, Toshifumi Tada1, Kojiro Michitaka2, Koichi Takaguchi3, Kunihiko Tsuji4, Ei Itobayashi5, Daichi Takizawa6, Masashi Hirooka7, Yohei Koizumi7, Hironori Ochi8, Koji Joko8, Yoshiyasu Kisaka9, Yuko Shimizu10, Kazuto Tajiri11, Joji Tani12, Tatsuya Taniguchi13, Akiko Toshimori14, Shinichi Fujioka15, Takashi Kumada1.   

Abstract

Patients with end-stage renal disease who are undergoing dialysis may be at high risk of developing hepatocellular carcinoma (HCC). We investigated the characteristics and prognosis of HCC in patients undergoing dialysis in Japan. Patients characteristics, progression of HCC at diagnosis, and survival rates after diagnosis were compared between 108 HCC patients undergoing dialysis and 526 non-dialysis patients followed up at liver center. The comparisons were also performed after adjusting for patient age, gender, platelet count, and etiology using propensity-score matching. HCC was more advanced in patients undergoing dialysis than in non-dialysis controls. The 3- and 5-year survival rates of patients undergoing dialysis were 56.3% and 38.3%, respectively, which were lower than those of non-dialysis controls (66.5% and 52.7%, respectively, P = 0.0026). The results were the same after propensity score matching (P = 0.0014). In Japan, HCC was more advanced at diagnosis in patients undergoing dialysis in comparison to HCC in patients at liver centers, resulting in a lower survival rate after diagnosis.
© 2017 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  Dialysis; Hepatocellular carcinoma; Prognosis; Progression; Surveillance

Mesh:

Year:  2017        PMID: 28880488     DOI: 10.1111/1744-9987.12563

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  5 in total

1.  A nomogram for predicting the risk of postoperative recurrence of hepatitis B virus-related hepatocellular carcinoma in patients with high preoperative serum glutamyl transpeptidase.

Authors:  Jia-Si Zhang; Zhi-Heng Wang; Xing-Gang Guo; Ji Zhang; Jun-Sheng Ni
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Chih-Chieh Ko; Yi-Hsiang Huang; Chien-Wei Su; Cheng-Yuan Hsia; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade.

Authors:  Shu-Yein Ho; Chia-Yang Hsu; Po-Hong Liu; Chih-Chieh Ko; Yi-Hsiang Huang; Chien-Wei Su; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Cancers (Basel)       Date:  2020-04-30       Impact factor: 6.639

4.  Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection.

Authors:  Yuzuru Sakamoto; Shingo Shimada; Toshiya Kamiyama; Ko Sugiyama; Yoh Asahi; Akihisa Nagatsu; Tatsuya Orimo; Tatsuhiko Kakisaka; Hirofumi Kamachi; Yoichi M Ito; Akinobu Taketomi
Journal:  World J Gastrointest Surg       Date:  2022-07-27

5.  A model combining TNM stage and tumor size shows utility in predicting recurrence among patients with hepatocellular carcinoma after resection.

Authors:  Yu Zhang; Shu-Wei Chen; Li-Li Liu; Xia Yang; Shao-Hang Cai; Jing-Ping Yun
Journal:  Cancer Manag Res       Date:  2018-09-20       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.